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Anovel sequence of 1,3,4-oxadiazoline derivatives has been synthesized with an endeavour to explore their consequence 
on in vitro growth of microbes causing the microbial contagion. In vitro antimicrobial activity has been performed against 
the Escherichia coli (E. coli) and Proteus mirabilis (P. mirabilis) which are Gram-negative (Gram-ve) and Staphylococcus 
aureus (S. aureus) and Staphylococcus epidermidis (S. epidermis) which are Gram-positive (Gram+ve) by using disk 
diffusion method. The minimum inhibitory concentration (MIC) has been distinguished by employing the double dilution 
method. The result of percent inhibition area/µg of the compounds has been differentiated with the standard drug 
“Ciprofloxacin”. Several compounds portray excellent activity as compared to the standard drug Ciprofloxacin while some 
of them presented a considerable zone of inhibition. The evaluated compounds for cytotoxicity effects via Human 
hepatocellular carcinoma (HepG2) cell line by MTT-assay and findings reveal that the experimental compounds display a 
viability of ≥80% at 100 µM. In molecular docking studies, the 1,3,4-oxadiazoline derivatives demonstrate the ligand-
receptor interaction with amino acids which exist on the active sites of the peptide deformylase and the 1,3,4-oxadiazoline 
derivatives exhibit their antibacterial potential as peptide deformylase inhibitors. 
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Contagious diseases are nowadays the second vital 
reason for widespread death and the third significant 
reason for death in developed countries (WHO 2002; 
Nathan 2004). The advancement of microbes concerning 
antimicrobial resistance (AMR) albeit an unavoidable 
aspect of the general evolution of bacteria is a major 
public health concern as it is extremely difficult to 
overcome (Courvalin 2005). Multidrug resistance 
(MDR) Gram-positive (Gram+ve) bacteria, as 
Methicillin-resistant Staphylococci aureus (MRSA), 
Penicillin resistant Streptococcus pneumoniae (PRSP), 
and Vancomycin-resistant Enterococci (VRE), produced 
difficulties in the therapeutics (K.R Babu et al; 2008; A. 
Dalhoff 1994). Compounds containing oxadiazole ring 
possess a variety of therapeutic potentials like anti-
inflammatory, antiviral, analgesic, antineoplastic, anti-
microbial, fungicidal, anticonvulsant, anti-proliferative, 
anti-mycobacterial, anti-protozoal, anti-diabetic, 
anthelmintic, hypoglycaemic, antiallergic, enzyme 
inhibitors, insecticidal, inhibition of tyrosinase, 
cathepsin K and anticancer activities (B. Shivi & M. K. 
Gupta 2011; M.O. Ahmed et al; 2002; R. Chawla et al; 
2010; N.N. Farshori et al; 2010; N. Bhardwaj et al; 
2009; B. Chandrakantha et al; 2010; M. Shaharyar et al; 
2010; H.S. athirajan et al; 2010; O. Parkash et al; 2010; 
M.M. Kumar et al; 2010; Y. Li et al; 2006; C.J. Chen 
et al; 2007; M. Islam et al; 2006; F. Liu et al; 2008; 
M.S. Karthikeyan et al; 2008; N.P. Rai et al; 2009; A. 
Husain & Ajmal 2009; S.G. Kucukguzel et al; 2002; O. 
Ates et al; 1998; V. Jakubkiene et al; 2003; M. Amir 
et al; 2004; T.M.C. Tan et al; 2006; A.S. Aboraia et al; 
2006; Y. Li et al; 2006; M.T. Khan et al; 2005; J.T. 
Palmer; et al; 2006; K.C.N Chaluvaraju et al; 2011). The 
inductive effect of extra heteroatom is responsible for 
the basic nature of oxadiazole on the other hand two 
pyridine type nitrogen in the structure diminishes the 
aromaticity to the point where oxadiazole exerts the 
resemblance with conjugated diene. The nucleus 
participates in a variety of chemical reactions like 
thermal photochemical and substitution (electrophilic & 
—————— 
Abbreviations: Antimicrobial resistance (AMR); Multidrug
resistance (MDR); Methicillin-resistant Staphylococci aureus
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Vancomycin-resistant Enterococci (VRE). 




nucleophilic), (R.N. Warrener et al; 2000). There are 
furthermore valuable intermediates in organic synthesis 
(M. Guan et al; 2003) and extensively working as 
electron transporting and hole-blocking resources 
(C.R.W. Guimaraes et al; 2005). In addition, 1,3,4-
oxadiazole heterocycles are especially good quality 
bioisosteres of amides and esters, which know how to 
contribute substantially to rising pharmacological 
activity by participating in hydrogen bonding 
interactions with the receptors (Guimaraes et al; 2005). 
Recently Liu et al. reported the antibacterial potential  
of 3-((5-phenyl-1,3,4-oxadiazol-2-yl) methyl)-2-
thioxothiazolidin-4-one derivatives (Liu et al; 2014). 
Ranjith et al. synthesized N-(4-(4-chloro-1H-imidazol-
1-yl)-3-methoxyphenyl) amide/sulfonamide derivatives 
and evaluated them for antimicrobial activity (P.K. 
Ranjith et al; 2014; C. Congio et al; 2008). On the other 
hand, the high biologicalpotential of the imidazole 
nucleus possessing drugs prompts scientists to produce 
better therapeutic compounds. Pharmacological potential 
of imidazole derivatives comprises anticancer  
(G. Aridoss et al; 2006) antimicrobial (L. Nagarapu  
et al; 2008; K. Bhandari et al; 2009; S. Emami et al; 
2008) and antioxidant (R.C. Smith et al; 1987). It is 
known that clinically useful drugs such as miconazole, 
econazole and oxiconazole having imidazole moiety 
exhibits strong antifungal activity. Metalloprotease 
subfamily enzyme, peptide deformylase from E. coli is 
an extremely conserved enzyme which PDB ID is 
1G2A. Peptide deformylase is a key factor for 
developing a new antibacterial agent (R. S Kumar et al; 
2011). Computational studies are a key factor for drug 
design. There is an enormous area of drug designing but 
one of them is the relationship between protein and 
chemical structure, which is possible by Docking 
studies, it determines probable by ligand-receptor 
binding manner (M. A Beg et al; 2018). Therefore,  
the biological importance of 1,3,4-oxadiazole and 
substituted nitroimidazole nucleus impelled us to aim 
and synthesize some new moieties which cover mutually 
the functional nucleus, as well as their combination, will 





All required components to complete the 
preparation of oxadiazoline derivatives were bought 
from Sigma, Merck, SRL and were consumed 
following the purification. Melting point (M.P) were 
analysed employing the instrument Melt-Tem.p.and 
were recorded as received. HeraeusVario EL III 
analyzer at CDRI, Lucknow, India was applied to 
carry out the Elemental analyses. IR, NMR (1H and 
13C) spectra are recorded on instrument Perkin-Elmer 
model 1600” FT-IR RX1 and Bruker AVANCE”300 
MHz spectrometers. The following abbreviations 
were applied as a singlet, s; doublet, d; double 
doublet, dd; triplet t; multiple, m; chemical shift, δ ;’ 
MICROMASS” QUATTRO” II triple quadrupole 
mass spectrometer was applied to mass spectrum. Pre-
coated silica gel aluminium sheets were employed for 
testing the purity and status of the reaction and 
observed under UV radiation. 
 
General procedure for the synthesis of compound 
(A1-A2) 
The concoction of 4-NO2-C3H4N2 or 2-CH3-4(5)-
NO2- C3H4N2 (1 mmol), ECA (C4H7ClO2) (1 mmol) 
and K2CO3 (1.5 mmol) in Dry-C3H6O (5-10 mL) was 
refluxed for one day. The reaction concoction was 
strained hot, and the liquid was removed by the 
filtration. The crude product thus received followed 
by the purification of recrystallization. 
Ethyl 2-(3,4-(NO2)2-1H-pyrazol-1-yl)acetate (A1): 
Yellow crystal (This compound was synthesized by the 
reaction between 4-nitroimidazole, ethylchloroacetate 
and K2CO3 under reflux condition Yellow, Yield 80%); 
IR: 1690, 1620; 1H NMR (DMSO-d6,500 MHz): δ 5.67 
(2H,s, CH2), 4.92 (2H,q, CH2), 2.70 (3H,s, CH3), 1.35 
(3H, t, CH3). 
Ethyl 2-(5-CH3-3,4--(NO2)2-1H-pyrazol-1-
yl)acetate(A2): Yellow crystal (This compound was 
synthesized by the reaction between 2-methyl-4(5)-
nitroimidazole, ethylchloroacetate and K2CO3 under 
reflux condition Yellow, Yield 86%); IR: 1686, 1626 
cm-1; 1HNMR (DMSO-d6,500 MHz): δ 7.7 (1H, s, CH), 
5.63 (2H, s, CH2), 4.90 (2H, q, CH2), 1.37 (3H, t, 
CH3). 
 
General procedure for the synthesis of compound 
(B1-B2) 
A concoction of compound A1 or A2 (2 mmol) and 
NH2NH2.H2O (2 mmol) in C2H5OH (10 mL) was 
refluxed for 10 h. A concrete mass of hydrazide B1-
B2 was received followed by cooling, straining and 
recrystallization. 
Ethyl 2-(3,4-dinitro-1H-pyrazol-1-yl) acetohydrazide 
(B1): White crystal (This compound was synthesized 
by the reaction between A1 and hydrazide in ethanol 
under reflux condition White, Yield 80%); IR: 3312, 
3214, 1693 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 




9.62 (1H, bs, NH), 4.82 (2H, bs, NH2), 2.94 (3H, s, 
CH3), 2.92 (3H, s, CH3). 
Ethyl 2-(5-methyl-3,4-dinitro-1H-pyrazol-1-yl) 
acetohydrazide (B2): White crystal (This compound 
was synthesized by the reaction between A2 and 
hydrazide in ethanol under reflux condition White, 
Yield 84%); IR: 3330, 3214, 1698 cm-1; 1H NMR 
(DMSO-d6,500 MHz): δ 9.64 (1H, bs NH), 4.84 (2H, 
bs, NH2), 2.94 (3H, s, CH3). 
 
General procedure for the synthesis of 
compound (C1-C2) 
On a stirrer the solution of hydrazide B1 or B2  
(1 mmol) and 3-hydroxy-4-methoxy-benzaldehyde  
(1 mmol) in C2H5OH (25 mL) was further added, 
followed by the drop wise adding up of glacial acetic 
acid (0.2 mL). The final concoction was refluxed for  
5 h, stirred, precipitated, assembled following the 
straining, drying and recrystallization to yield C1-C2 
in varying yields. 
(E)-N-(3-hydroxy-4-methoxybenzylidene)-2-
(3,4-dinitro-1H-pyrazol-1-yl)acetohydrazide (C1): 
White crystal (This compound was synthesized by the 
reaction between B1 and 3-hydroxy-4-methoxy-
benzaldehyde in ethanol under reflux condition 
White, Yield 82%); IR: 3350, 3212, 1693, 1617 cm-1; 
1H NMR (DMSO-d6,500 MHz): δ 9.62 (1H, broad s, 
NH), 8.12 (1H, s, CH=N), 7.64 (1H, m, CH-Ar), 5.76 
(2H, s, CH2 ), 5.30 (1H, s, OH), 3.79 (3H, s, OCH3), 
2.93 (3H, s, CH3), 2.90 (3H, s, CH3). 
(E)-N-(3-hydroxy-4-methoxybenzylidene)-2-(5-
methyl-3,4-dinitro-1H-pyrazol-1-yl) 
acetohydrazide (C2): White crystal (This compound 
was synthesized by the reaction between B2 and  
3-hydroxy-4-methoxy-benzaldehyde in ethanol under 
reflux condition White, Yield 86%); IR: 3360, 3218, 
1692, 1620 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 
9.64 (1H, broad s, NH), 8.14 (1H, s, CH=N), 7.64 (1H, 
m, CH-Ar), 5.32 (1H, s, OH), 5.70 (2H, s, CH2), 3.78 
(3H, s, OCH3), 2.92 (
3H, s, CH3). 
 
General procedure for the synthesis of compound 
(D1-D2) 
In an RB (Round bottomed flask) (D1 or D2(1 
mmol) and 20 mL of acetic anhydride was reacted for 
12 h under reflux. After this the concoction was kept 
cooling and the poured to ice cooled water and stirred 
to get precipitate now the straining, purification and 




3(2H)-yl)ethanone (D1): Yellow crystal (This 
compound was synthesized by the reaction between 
C1 and acetic anhydride under reflux condition 
Yellow, Yield 70%); IR: 3410, 1716, 1617, 1258 cm-1; 
1H NMR (DMSO-d6,500 MHz): δ 7.80 1H, (m, CH-
Ar), 5.32 (s, 1H, OH), 3.80 (3H, s, OCH3), 2.96 (3H, 
s, CH3), 2.98 (3H, s, CH3), 2.52 (3H, s, COCH3). 
1-(2-(3-hydroxy-4-mrthoxyphenyl)-5-((5-methyl-
3,4-dinitro-1H-pyrazol-1-yl)methyl)-1,3,4-oxadiazol-
3(2H)-yl)ethanone (D2): Yellow Crystals (This 
compound was synthesized by the reaction between C2 
and acetic anhydride under reflux condition Yellow, 
Yield 75%); IR: 3400, 1715, 1620, 1255; 1H NMR 
(DMSO-d6,500 MHz): δ 7.62 (1H, m, CH-Ar), 5.34 
(1H, s, OH), 3.82 (3H, s, OCH3), 2.92 (3H, s, CH3), 2.54 
(3H, s, COCH3), 2.52 (3H, s, COCH3). 
 
Common approach for the preparation of 
compound (1-14) 
A concoction of compound D1 or D2 (1 mmol) and 
corresponding sulfonyl chloride (1 mmol) in acetone (20 
ml) was stirred at 0-5°C for 10 h. The solid precipitate 





White crystals (This compound was synthesized by 
the reaction between D1 and benzene sulphonyl chloride 
in acetone at 0-5°C and obtained as white crystal, White, 
Yield 75%) m.p.250-252°C; IR: 3068,1675, 1648, 
1255,1158 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 
8.660 (s, 1H, Ar-H), 8.218 (1H, s, Ar-H), 8.212 (1H, s, 
Ar-H), 7.930 (1H, s, Ar-H), 7.851 (1H, d, J=7.5, Hz, Ar-
H), 7.805 (1H, d, J=21, Hz, Ar-H), 7.653-7.703 (1H, m, 
Ar-H), 7.552 (1H, s, Ar-H), 7.462 (1H, d, J=8.4, Ar-H), 
7.283 (1H, d, J=8.1, Ar-H), 3.838 (3H, s, OCH3), 2.508 
(3H, s, COCH3);
 13C NMR (DMSO-d6,500 MHz): δ 
161.20 (CO), 151.90 (C=N), 140.50, 139.87, 134.49, 
134.16, 130.66, 130.16, 124.72, 122.26, 112.26, 56.09 
(OCH3), 24.21 (CH3). ESI-MS: m/z [M
++1], 487.04 
(Calcd 487.07). Anal. calc. for C20H17N5O8S: C, 49.28; 





Creamy white crystals (This compound was 
synthesized by the reaction between D1 and p-




methylbenzene sulphonyl chloride in acetone at 0-5°C 
and obtained as creamy White crystals, creamy White 
crystals, Yield 78%); m.p.246-248°C; IR: 3030, 1670, 
1650 1258, 1160 cm-1;1H NMR (DMSO-d6,500 
MHz): δ 8.639 (1H, s, Ar-H), 8.222 (1H, s, Ar-H), 
8.216 (1H, s, Ar-H), 7.724 (2H, d, J=8.1, Hz,Ar-H), 
7.533 (1H, s, Ar-H), 7.459 (2H, d, J=6.9, Hz,Ar-H), 
7.431 (1H, d, J=2.7, Hz,Ar-H), 7.219 (1H, d, J=8.4, 
Hz, Ar-H), 3.800 (3H, s, OCH3), 2.501 (3H, s, 
COCH3), 2.43 (1H, s, CH3); 
13C NMR (DMSO-d6,500 
MHz): δ 161.25 (CO); 151.94 (C=N), 139.83, 140.52, 
134.18, 134.52, 23.46 (CH3), 130.64, 130.18, 124.70, 
122.24, 112.23, 56.14 (OCH3), 24.22 (COCH3); ESI-
MS: m/z [M++1], 502.14 (Calcd 502.10). Anal. calc. 
for C21H19N5O8S: C, 50.30; H, 3.82; N, 13.97. Found: 





White crystals (This compound was synthesized by 
the reaction between D1 and 4-methoxybenzene 
sulphonyl chloride in acetone at 0-5°C and obtained  
as white crystal, White crystal, Yield 80%); m.p.256-
258°C; IR: 3022, 1660, 1640, 1260,1152 cm-1; 1H 
NMR (DMSO-d6,500 MHz): δ 8.661 (1H, s,Ar-H), 
8.451 (2H, d, J=8.4, Hz,Ar-H), 8.224 (1H, s, Ar-H), 
8.216 (1H, s, Ar-H), 8.136 (2H, J d, =8.4, Hz,Ar-H), 
7.560 (1H, s, Ar-H), 7.471 (1H, d, J=8.1, Ar-H), 7.321 
(1H, d, J=8.4, Ar-H), 3.839 (3H, s, OCH3), 3.838 (3H, 
s, OCH3), 2.508 (3H, s, COCH3); 
13C NMR (DMSO-
d6,500 MHz): δ 161.26 (CO), 151.92 (C=N), 140.54, 
139.87, 134.45, 134.19, 130.67, 130.19, 124.68, 
122.30, 112.28, 56.14 (OCH3), 24.5 (CH3); ESI-MS: 
m/z [M++1], 518.1 (Calcd 518.09). Anal. Calcd for 
C21H18N5O9S: C, 48.84; H, 3.51; N, 13.56. Found: C, 





Light yellow crystals (This compound was 
synthesized by the reaction between D1 and 4-
chlorobenzene sulphonyl chloride in acetone at 0-5°C 
and obtained as Light yellow crystal, Light yellow, 
Yield 74%); m.p.250-252°C; IR: 3074, 1670, 1650, 
1266,1150 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 
8.660 (1H, s, Ar-H), 8.219 (1H, s, Ar-H), 8.215 (1H, 
s, Ar-H), 7.887 (2H, d, J=9.3, Hz,Ar-H), 7.767 (2H, d, 
J=9.3, Hz, Ar-H), 7.553 (1H, s, Ar-H), 7.463 (1H, d, 
J=9.6, Hz,Ar-H), 7.282 (1H, d, J=8.4, Hz,Ar-H), 
3.839 (3H, s, OCH3), 2.504 (3H, s, COCH3); 
13C 
NMR (DMSO-d6,500 MHz): δ 161.29 (CO), 151.95 
(C=N), 140.57, 139.89, 134.48, 134.16, 130.65, 
130.13, 124.75, 122.27, 112.29, 56.14 (OCH3), 24.3 
(CH3); ESI-MS: m/z [M
++1], 522.08 (Calcd 522.04). 
Anal. Calcd for C20H15ClN5O8S: C, 46.12; H, 2.90; N, 





White crystals (This compound was synthesized by 
the reaction between D1 and 3-bromobenzene 
sulphonyl chloride in acetone at 0-5°C and obtained 
as white crystal, white, Yield 78%); m.p.256-258°C; 
IR: 3070, 1680, 1655, 1270, 1165 cm-1; 1H NMR 
(DMSO-d6,500 MHz): δ 8.841 (1H, s, Ar-H), 8.363 
(1H, d, J=13.5, Hz,Ar-H), 8.173 (1H, d, J=12.9, 
Hz,Ar-H), 8.015 (1H, d, J=7.8, Hz,Ar-H), 7.946 (1H, 
s, Ar-H), 7.850 (1H, s, Ar-H), 7.808 (1H, d, J=8.1, 
Hz,Ar-H), 7.408-7.505 (1H, m, Ar-H), 3.834 (3H, s, 
OCH3), 2.505 (3H, s, COCH3); 
13C NMR (DMSO-
d6,500 MHz): δ 161.29 (CO), 151.91 (C=N), 140.50, 
139.81, 134.43, 134.15, 130.61, 130.15, 124.72, 
122.29, 112.25, 56.10 (OCH3), 24.27 (CH3); ESI-MS: 
m/z [M++1], 566.12 (Calcd 566.98). Anal. Calcd for 
C20H15BrN5O8S: C, 42.49; H, 2.67; N, 12.39. Found: 




Creamy white crystals (This compound was 
synthesized by the reaction between D1 and 4-
bromobenzene sulphonyl chloride in acetone at 0-5°C 
and obtained as white crystal, white, Yield 70%); 
m.p.252-254°C; IR: 3068, 1668,1658, 1245,1160 cm-
1; 1H NMR (DMSO-d6,500 MHz): δ 8.665 (1H, s, Ar-
H), 8.223 (1H, s, Ar-H), 8.217 (1H, s, Ar-H), 7.885 
(2H, d, J=8.4, Hz,Ar-H), 7.766 (d, J=8.7, 2H, Hz,Ar-
H), 7.555 (1H, s, Ar-H), 7.462 (1H, d, J=8.4, Hz,Ar-
H), 7.284 (1H, d, J=8.7, Ar- H), 3.832 (3H, s, OCH3), 
2.509 (3H, s, COCH3); 
13C NMR (DMSO-d6,500 
MHz): δ 161.23 (CO), 151.90 (C=N), 140.51, 139.86, 
134.43, 134.17, 130.60, 130.16, 124.68, 122.24, 
112.26, 56.17 (OCH3), 24.29 (CH3); ESI-MS: m/z 
[M++1], 566.20 (Calcd 566.98). Anal. calc. for 
C20H15BrN5O8S: C, 42.49; H, 2.67; N, 12.39. Found: 
C, 42.40; H, 2.88; N, 12.40%. 
4-(3-acetyl-2,3-dihydro-5-(4-nitro-1H-imidazol-
1-yl)-1,3,4-oxadiazol-2-yl)-2-methoxyphenyl-4-nitro-




benzenesulfonate (7): Yellow crystals (This 
compound was synthesized by the reaction between 
D1 and 4-nitrobenzene sulphonyl chloride in acetone 
at 0-5°C and obtained as yellow crystal, yellow, Yield 
95%)m.p.260-262°C; IR: 3030, 1672, 1656,1252, 
1160 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 8.662 
(1H, s, Ar-H); 8.211 (1H, s, Ar-H), 8.208 (1H, s, Ar-
H), 7.888 (2H, d, J=8.1, Hz,Ar-H), 7.769 (2H, d, 
J=8.4, Hz,Ar-H), 7.556 (1H, s, Ar-H), 7.464 (1H, d, 
J=8.1, Hz,Ar-H), 7.285 (1H, d, J=8.1, Hz,Ar-H), 
3.837 (3H, s, OCH3), 2.507 (3H, s, COCH3); 
13C 
NMR (DMSO-d6,500 MHz): δ 161.22 (CO), 151.92 
(C=N), 140.48, 139.85, 134.48, 134.12, 130.65, 
130.13, 124.74, 122.26, 112.28, 56.10 (OCH3), 24.22 
(CH3); ESI-MS: m/z [M
++1], 532.55 (Calcd 532.60). 
Anal. Calcd for C20H15N6O10S: C, 45.20; H, 2.84; N, 
15.81. Found: C, 45.23; H, 2.58; N, 15.90%. 
4-(3-acetyl-2,3-dihydro-5-(2-methyl-4,5-dinitro-
1H-imidazol-1-yl)-1,3,4-oxadiazol-2-yl)-2-
methoxyphenylbenzenesulfonate (8):White crystals 
(This compound was synthesized by the reaction 
between D2 and benzene sulphonyl chloride in 
acetone at 0-5°C and obtained as white crystal, white, 
Yield 95%) m.p.248-250°C; IR: 3055, 1678, 1644, 
1258,1164, cm-1; 1H NMR (DMSO-d6,500 MHz): δ 
8.662 (1H, s, Ar-H), 8.432 (2H, d, J=8.7, Hz,Ar-H), 
8.110 (2H, d, J=8.7, Ar-H), 7.307-7.477 (5H, m, Ar-
H), 3.839 (3H, s, OCH3), 2.52 (3H, s, CH3), 2.488 
(3H, s, COCH3); 
13C NMR (DMSO-d6,500 MHz): δ 
164.75 (CO), 152.23 (C=N), 140.58, 134.62, 131.64, 
24.5 (CH3), 126.56, 124.78, 122.34, 115.43, 112.12, 
56.52 (OCH3), 24.4 (CH3); ESI-MS: m/z [M
++1], 
546.1 (Calcd 546.07). Anal. Calcd for C21H17N6O10S: 






White crystals (This compound was synthesized by 
the reaction between D2 and p-methylbenzene 
sulphonyl chloride in acetone at 0-5°C and obtained 
as white crystal, white, Yield 95%); m.p.254-256°C; 
IR: : 3030, 1673, 1652, 1252,1162 cm-1; 1H NMR 
(DMSO-d6,500 MHz): δ 8.648 (1H, s, Ar-H), 7.726 
(2H, d, J=7.8, Hz,Ar-H), 7.538 (1H, s, Ar-H), 7.461 
(2H, d, J=7.8, Hz,Ar-H), 7.434 (1H, d, J=1.8, Hz, Ar-
H), 7.221 (1H, d, J=8.1, Hz,Ar-H), 3.830 (3H, s, 
OCH3), 2.508 (3H, s, COCH3), 2.504 (s, 3H, CH3), 
2.433 (s, 3H, CH3); 
13C NMR (DMSO-d6,500 MHz): 
164.52 (CO), 152.76 (C=N), 140.23, 134.82, 131.35, 
126.41, 124.67, 122.88, 115.42, 112.13, 56.40 
(OCH3), 24.5 (CH3), 24.3 (CH3); ESI-MS: m/z 
[M++1], 560.12 (Calcd 560.09). Anal. Calcd for 
C22H19N6O10S: C, 47.23; H, 3.42; N, 15.02. Found: C, 





White crystals (This compound was synthesized by 
the reaction between D2 and 4-methoxybenzene 
sulphonyl chloride in acetone at 0-5°C and obtained 
as white crystal, white, Yield 95%); m.p.258-260°C; 
IR: 3070, 1672, 1654, 1260,1162 cm-1; 1H NMR 
(DMSO-d6,500 MHz): δ 8.665 (1H, s, Ar-H); 7.846 
(2H, d, J=8.7, Hz,Ar-H), 7.739 (2H, d, J=8.4, Hz,Ar-
H), 7.546 (1H, s, Ar-H), 7.459 (1H, d, J=7.8, Hz,Ar-
H), 7.280 (1H, d, J=8.4, Hz,Ar-H), 3.834 (3H, s, 
OCH3), 3.832 (3H, s, OCH3), 2.508 (s, 3H, COCH3), 
2.501 (s, 3H, CH3); 
13C NMR (DMSO-d6,500 MHz): 
δ 164.93 (CO), 24.62 (CH3), 152.42 (C=N), 140.74, 
134.63, 131.25, 126.19, 124.73, 122.57, 115.35, 
112.08, 56.44 (OCH3), 56.17 (OCH3), 24.53 (CH3); 
ESI-MS: m/z [M++1], 576.1 (Calcd 576.08). Anal. 
Calcd for C22H19N6O11S: C, 45.92; H, 3.33; N, 14.60. 





yellow crystals (This compound was synthesized by the 
reaction between D2 and 4-chlorobenzene sulphonyl 
chloride in acetone at 0-5°C and obtained as light-
yellow crystal, yellow, Yield 95%); m.p.246-248oC; 
IR: 3022, 1670, 1652, 1250,1160 cm-1; 1H NMR 
(DMSO-d6,500 MHz): δ 8.664 (1H, s, Ar-H), 7.844 
(1H, d, J=8.7, Hz,Ar-H), 7.736 (2H, d, J=8.7, Hz,Ar-
H), 7.548 (1H, s, Ar-H), 7.457 (1H, d, J=8.7, Hz,Ar-H), 
7.282 (1H, d, J=8.7, Hz,Ar-H), 3.836 (3H, s, OCH3), 
2.506 (3H, s, COCH3), 2.48 (3H, s, CH3); 
13C NMR 
(DMSO-d6,500 MHz): δ 164.37 (CO), 152.53 (C=N), 
140.91, 134.19, 131.04, 126.72, 124.48, 122.61, 
115.37, 112.54, 56.41 (OCH3), 24.52 (CH3), 24.35 
(CH3); ESI-MS: m/z [M
++1], 580.06 (Calcd 580.03). 
Anal. Calcd for C21H16ClN6O10S: C, 43.49; H, 2.78; N, 





(12):Creamy white crystals (This compound was 
synthesized by the reaction between D2 and 3-




bromobenzene sulphonyl chloride in acetone at 0-5°C 
and obtained as creamy white crystal, creamy white, 
Yield 95%); m.p.262-264oC; IR: 3018, 1678, 1654, 
1262,1155 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 
8.655 (1H, s, Ar-H), 7.933 (1H, s, Ar-H), 7.852-7.877 
(1H, d, Ar-H), 7.806 (1H, d, J=7.2, Hz,Ar-H), 7.653 
(1H, m, Ar-H), 7.534 (1H, s, Ar-H), 7.445 (1H, d, 
J=7.5, Hz,Ar-H), 7.248 (1H, d, J=8.1, Hz,Ar-H), 
2.504 (3H, s, COCH3), 3.833 (3H, s, OCH3), 2.54 
(3H, s, CH3); 
13C NMR (DMSO-d6,500 MHz): δ 
164.47 (CO), 152.97 (C=N), 140.55, 134.33, 131.74, 
126.19, 124.80, 122.43, 115.67, 112.76, 56.42 
(OCH3), 24.72 (CH3), 24.54 (CH3); ESI-MS: m/z 
[M++1], 625.2 (Calcd 625.98). Anal. calc. for 
C21H16BrN6O10S: C, 40.40; H, 2.58; N, 13.46. Found 





White crystals (This compound was synthesized by 
the reaction between D2 and 4-bromobenzene 
sulphonyl chloride in acetone at 0-5oC and obtained as 
white crystal, white crystal, Yield 95%); m.p.256-
258oC; IR: 3060, 1675, 1642, 1248, 1162 cm-1; 1H 
NMR (DMSO-d6,500 MHz): δ 8.664 (1H, s, Ar-H), 
7.760 (2H, d, J=9.9, Hz,Ar-H), 7.534 (2H, s, Ar-H), 
7.435 (1H, d, J=9.9, Hz,Ar-H), 7.227 (1H, d, J=9.3, 
Hz,Ar-H), 7.112 (1H, d, J=22.8, Hz,Ar-H), 3.870 (3H, 
s, OCH3), 2.501 (3H, s, CH3), 2.506 (3H, s, COCH3); 
13C NMR (DMSO-d6,500 MHz): δ 164.26 (CO), 
152.19 (C=N), 140.64, 134.21, 131.76, 24.29 (CH3), 
126.55, 124.34, 122.69, 115.43, 112.38, 56.49 
(OCH3), 24.25 (CH3); ESI-MS: m/z [M
++1], 625.2 
(Calcd 625.98). Anal. calc. for C21H16BrN6O10S: C, 




methoxyphenyl-4-nitrobenzenesulfonate (14): Yellow 
crystals (This compound was synthesized by the reaction 
between D2 and 4-nitrobenzene sulphonyl chloride in 
acetone at 0-5oC and obtained as yellow crystal, yellow, 
Yield 95%); m.p.264-266°C. Anal. calc. for 
C21H16N7O12S: C 42.72, H 2.73, N 16.61% found C 
42.70, H 2.70, N 16.64%; IR: 3058, 1665, 1642, 
1265,1166 cm-1; 1H NMR (DMSO-d6,500 MHz): δ 
8.662 (1H, s, Ar-H), 7.762 (2H, d, J=8.7, Hz,Ar-H), 
7.538 (1H, s, Ar-H), 7.438 (2H, d, J=10.2, Hz,Ar-H), 
7.225 (1H, d, J=8.4, Hz,Ar-H), 7.115 (1H, d, J=2.1, 
Hz,Ar-H), 3.836 (3H, s, OCH3), 2.501 (3H, s, CH3), 
2.507 (3H, s, COCH3); 
13C NMR (DMSO-d6,500 MHz): 
δ 164.67 (CO), 152.44 (C=N), 140.38, 134.56, 131.67, 
126.59, 124.28, 122.45, 115.36, 112.27, 56.42 (OCH3), 
24.29 (CH3), 24.24 (CH3); ESI-MS: m/z [M
++1], 591.09 
(Calcd 591.06). Anal. calc. for C21H16N7O12S: C, 42.72; 
H, 2.73; N, 16.61. Found: C, 42.70; H, 2.70; N, 16.64%. 
 
Biological Activity 
The disc diffusion plan following some improvement 
was employed to carry out the in vitro antibacterial 
assessment utilizing the bacterial culture of strains (S. 
aureus, S. epidermidis, P. mirabilis, and E. coli) that 
were cultivated consuming the agar media with 
incubation at 37°C for 18 h. Applying the McFarland 
protocol the cells were stretched for incubation in a 
solution of salt to yield a suspension of around 105 
CFU/ml. Pouring the concoction (suspension 10 ml 
antibiotic agar at 40°C) onto a Petri-plate under the 
laminar flow cabinet and after this, the paper disks of 
6.0mm was established on it. The compound to be 
screened (1 mg) disbanded in DMSO (100 ml) to 
produce a stock solution which was poured over the 
Petri-plate following further dilutions with different 
concentrations. In the estimation ciprofloxacin and 
DMSO were applied as positive and negative control 
respectively. Production of an inhibitory zone 
declared the sensitivity of the bacteria to the 
compounds studied after at 18 h on 36°C. The zone of 
inhibition for the oxadiazoline derivatives (1-14). 
The findings be matched among the Ciprofloxacin, 
and the inhibitory zone was elucidated at the lowest 
concentration that is responsible to prevent the growth 
of bacteria minimum inhibitory concentration (MIC). 
MIC was calculated by using the macro-dilution 
method applying for the benchmark inoculums of 105 
CFL/ml. The serial dilutions of the compounds to be 
evaluated was assembled to the final concentrations of 
400, 200, 100, 50, 12.5, 6.25 and 3.125µg/ml. The 
inhibition of the visible growth is observed after 18h 
incubation and the findings are recorded. 
 
Cytotoxicity studies (MTT-assay) 
 
Cell culture 
Culturing of HepG2 cell line was performed into 
DMEM medium with FBS (10%), penicillin (100 
units ml-1), streptomycin (100 μg ml-1), and 
amphotericin B (2.5 μg ml-1) at 37°C under 95% 
air/5% CO2 atmosphere (T. Mosmann 1983). To 
sustain the exponential growth HepG2 cell line were 
harvested when there is 80% confluence. 





To observe the viability of cells, MTT [(3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl) tetrazolium 
bromide], the assay is performed that is a colorimetric 
method based on the principle that only the viable 
cells can split the tetrazolium salt by using 
mitochondrial dehydrogenase (T. Mosmann; 1983). 
The harvesting of the cell monolayer was  
carried out by applying 0.25% trypsin to get single 
cell suspension followed by pipetting repeatedly.  
The cells that are growing exponentially were  
plated at 1.2 × 104 cells per well into 96-well 
microtiter plates following the incubation upto  
48 hours before the addition of the tested compounds 
to attain the highest confluency. The compounds  
to be tested were dissolved in 10% (v/v) DMSO to 
produce a stock solution that was again diluted with 
the new medium to get a 1 M concentration. The 
incubation for the cells with different concentrations 
of reference as well as the compounds was done for 
48 h at 37°C in 5% CO2 in combination with the 
control. At selected time periods PBS was utilized to 
wash the cells, the cells were the treated with 50 μl 
MTT solution and entered the incubation for 4 h. 
After incubation, the medium was eliminated and 
fresh DMSO 150 µl was added to each well and 
subjected to evaluate the absorbance at 570 nm at a 
wavelength of 655 nm on a Microplate reader (iMark, 
BIORAD, S/N 10321). All the experiments were 
carried out in triplicate and viability (%) was 
calculated. 
 
Molecular Docking Studies 
The interaction analysis of the protein-ligand 
binding site was done by the molecular docking 
analysis where we are using the AutoDock tool (G. M 
Morris et al; 2009) and the 3D interaction analysis in 
between protein-compound is visualized by LigPlot+ 
(R.A Laskowski, and M.B. Swindells; 2011). After 
the result of MIC and Zone inhibition test compounds 
which performed as good activity those docked. Our 
synthesized compound’s structure was draw by using 
ChemBioDraw Ultra 14.0 and making 3D format by 
using Chem3D Pro 14.0 (K. R Cousins; 2011 and 
M.A. Beg et al; 2021). The target compounds docked 
with the E. coli protein-peptide deformylase which 
PDB ID_1G2A(S. Bala et al; 2014). The binding 
affinity of the interactive amino acids with the PDB 
ID_1G2A and compared their binding affinity with 
the standard drug Ciprofloxacin. 





methoxyphenyl-4-benzenesulfonate (1-14) were 
synthesized by using a multi-step reaction process 
scheme as shown in Scheme I and Table I. Synthesis of 
the target compounds involves five steps, in the  
first step compounds (A1-A2) were obtained by the 
simple reaction of substituted nitroimidazole and ethyl 
chloroacetate in presence of potassium carbonate under 
reflux condition. Compounds (A1-A2) on reaction  
with hydrazine hydrate yields their corresponding 
hydrazides. (B1-B2) when reacted with 3-hydroxy-4-
methoxy-benzaldehyde in ethanol yield compounds 
(C1-C2). In the fourth step compounds (C1-C2) were 
refluxed with acetic anhydride to obtain oxadiazoline 
analogues (D1-D2). In the final step, oxadiazoline 
analogues were treated with substituted sulfonyl 
chloride with stirring at 0-5°C. The compounds were 
obtained in high yields and were appropriately 
characterized. Spectral data like IR, 1HNMR, 13CNMR, 
ESI-MS and elemental analyses were found in accord  
 
 
Scheme I — Schematic representation of the route adopted for the
synthesis of oxadiazoline derivatives 1-14, where “R1, R2 and R3” 
correspond to different substituents as mentioned in Table 1. 





Table I — Showing different substituent R1, R2 and R3 indicated as in Figure 1 
Compd R1 R2 R3 
1 H NO2 
 
2 H NO2 
CH3
 
3 H NO2 
OCH3
 
4 H NO2 
Cl
 
5 H NO2 
Br  
6 H NO2 
Br
 
7 H NO2 
NO2
 
8 CH3 NO2 
 
9 CH3 NO2 
CH3
 
10 CH3 NO2 
OCH3
 
11 CH3 NO2 
Cl
 
12 CH3 NO2 
Br  
13 CH3 NO2 
Br
 
14 CH3 NO2 
NO2
 




with the anticipated structure of the compounds. The 
purity was established by the pointed melting-point and 
the elemental analysis. The selected diagnostic bands 
of the IR spectra of compounds (1-14) provided 
evidential support for constructing the expected 
structure. In addition to common bands which arise due 
to ν(C=C) of the aromatic region and benzene some 
other bands also appear in IR spectra which gives the 
key information about the conversion of reactants in a 
schematic representation shown in Scheme I. The 
compounds (A1-A2) showed stronger peaks in the 
regions near 1690-1686 cm-1 due to ν(C=O) vibration 
which provide strong evidence for the formation of 
ester. A peak in the region 3412-3330 cm-1 and 3212-
3214 cm-1 due to the presence of NH2 and NH 
confirmed the conversion of esters into their 
corresponding hydrazide (B1-B2). Formation of 
compounds (C1-C2) was ascertained by the 
disappearance of the peak in the region 3412-3330 cm-1 
due to NH2 and by the presence of a peak in the range 
of 3350-3360 cm-1 assigned to a hydroxyl group. The 
presence of peak at around 1617-1620 cm-1 due to 
(HC=N) supports the formation of Schiff base. 
Structural confirmation for the compounds (D1-D2) is 
achieved by the presence of a peak in the region 1255-
1258 cm-1 and 1715-1716 cm-1 dueto presence of 
(COC) and (C=O). The disappearance of a peak at 
around 1617-1620 cm-1 due to (HC=N) also provide 
strong confirmation. Structural confirmation for the 
compounds (1-14) was obtained by the disappearance 
of peak in the range of 3350-3360 cm-1 due to the 
presence of hydroxyl group as well as due to the 
presence of peak at around 1150-1172 cm-1 and 1245- 
1270 cm-1 due to the existence of (S=O) and (COC) 
further confirms the formation of compounds (1-14). 
The structure of the oxadiazoline derivatives (1-14) 
compounds was further confirmed by 1HNMR spectra. 
Presence of a triplet at around 1.35-1.37 ppm and a 
quartet at 4.90-4.92 ppm due to CH3 and CH2 strongly 
recommend the formation of compounds (A1-A2). The 
formation of compounds (B1-B2) was confirmed by 
the absence of triplet and quartet due to CH3 and CH2 
and by the appearance of broad singlet at 9.62-9.64 and 
4.82-4.84 ppm due to NH and NH2 respectively. The 
absence of broad singlet at 4.82-4.84 ppm due to NH2 
and presence of a singlet at 8.12-8.14 ppm due to 
CH=N reveal the formation of compounds (C1-C2). 
Formation of compounds (D1-D2) was supported by 
the absence of a singlet at 8.12-8.14 ppm due to CH=N 
and a broad singlet at 9.62-9.64ppm due to NH. 
Formation of the compounds (1-14) was definite by the 
nonappearance of singlet at around 5.32-5.34 ppm due 
to OH. The structure of all compounds was further 
confirmed by 13CNMR, and all the characteristic peaks 
are shown in experimental data. 
 
Physicochemical properties, lipophilic efficiency, 
and PAINS rule analysis 
In drug development failure there are many causing 
factors some of them are poor solubility and poor 
permeability. Therefore, determining physiochemical 
properties with a compound is important and it is 
done by using the SwissADME online server which 
use SDF file of the chemical structure (A. Dania et al; 
2017). In generally we believed that the high 
molecular weight (M.W.) and high lipophilicity (C 
log P) have poor oral drug properties, but no doubt 
1/3 FDA approved are high M.W. C log P values in 
between 2-3 considered as optimal for an oral drug. 
PAINS (pan-assay interference compounds) which 
describe seeming bioactive molecules that can 
interfere in readout done interaction with dissimilar 
biological targets PAINS must be recognised and 
evaded in biochemical and pharmacological assay 
instruction to avoid false outcomes (J. B. Baell  
and G. A. Holloway; 2010). In Table II there (1-14) 
derivatives of 1,3,4-oxidazole listed of these 
physicochemical properties, lipophilic efficiency and 
PAINS rule are given which suggested the active 
compounds is vital for drug discovery effort. 
 
Biological Activity 
Antibacterial therapeutic effect of the prepared 
compounds (1-14) was investigated utilizing the four 
distinct cultures Gram-ve (E. coli andP. mirabilis) and 
Gram+ve (S. aureus andS. epidermidis). MIC was 
calculated by diluting the compounds for study and 
the findings were compared with the referenced 
Table III. First, the compounds to be tested were 
dissolved in the DMSO, the serial dilutions were 
made to the concentrations of 400, 200, 100, 50, 12.5, 
6.25, 3.125 µg/ml-1 and added to the 24 h old 
inoculums. The effect was reported after 18 hr when 
the formation of the inhibition zone appears in 
Table IV. At MIC, the zone of inhibition was 
calculated in comparison with the standard and the 
percent are of inhibition was also estimated per 
microgram of the tested compounds and compared 
with standard drug Ciprofloxacin (Figure 1). When 
the zone of inhibition was calculated against standard 
drug it is found that some of the compounds were 




found to show little to moderate activity in 
comparison to the standard drug. While some 
compounds (3, 7, 8, 13 and 14) showed 90% 
resemblance with the standard drug “Ciprofloxacin” 
against all the bacteria studied. On the other hand, 
compound (9) showed better activity than a standard 
drug in a case of S. aureus and found to possess 
significant activity against rest of the bacteria.The 
novel sequence of the oxadiazoline derivative was 
synthesized with a target that the newly synthesized 
compounds might be more potential therapeutic 
antibacterial agents. So, a complete investigation 
related to Cytotoxicity, antibacterial activity, and 
SAR (structure activity relationship) was carried out. 
Cytotoxicity studies 
The mitochondria of viable cells possess succinate 
dehydrogenase which reduced MTT to insoluble  
purple formazan crystal that can be measured 
spectrophotometer after solubilisation (H. Garn  
et al;1994; S. M. Thom et al;1993). Only the active 
cells can produce formazan crystal, so the number of 
active cells is directly proportional to the amount of 
formazan formed (S.H. Kim et al; 2002; S.R. Kim  
et al; 2003; Y.R. Lina et al; 2003; M.K. Gupta et al; 
2006). To find out the cytotoxicity effect, the active 
compounds were subjected to the MTT assay utilizing 
(HepG2) cell line.The studied compounds were taken 
in the range 3.125-100µm and the percent viability of 







Rotatable bonds Molar Refractivity C log P PAINS/ alert 
1 546.47 12 0 10 138.63 1.23 Y 
2 560.49 12 0 10 143.60 1.55 Y 
3 576.49 13 0 11 145.12 1.18 Y 
4 580.91 12 0 10 143.64 1.76 Y 
5 625.36 12 0 10 146.33 1.74 Y 
6 625.36 12 0 10 146.33 1.85 Y 
7 591.46 14 0 11 147.45 0.54 Y 
8 560.49 12 0 10 143.60 1.57 Y 
9 574.52 12 0 10 148.57 1.88 Y 
10 594.94 12 0 10 148.61 2.07 Y 
11 594.94 12 0 10 148.61 2.07 Y 
12 639.39 12 0 10 151.30 2.14 Y 
13 639.39 12 0 10 151.30 2.15 Y 
14 605.49 14 0 11 152.42 0.85 Y 
Y: means zero alert (PAINS rule) 
 
Table III — Representing minimum inhibitory concentration of oxadiazoline derivatives 1-14 Ciprofloxacin used as standard 
Compd 
Minimal Inhibitory Concentration (MIC) µg/ml 
Gram positive (Gram+ve) Gram negative (Gram-ve) 
S. aureus S. epidermidis P. mirabilis E. coli 
1 >100 >100 >100 >100 
2 >100 >100 >100 >100 
3 6.25 3.125 6.25 >100 
4 50 50 25 >100 
5 25 100 25 12.5 
6 >100 50 >100 >100 
7 6.25 3.125 12.5 >100 
8 12.5 3.125 100 >100 
9 6.25 6.25 6.25 25 
10 50 >100 >100 100 
11 >100 >100 >100 12.5 
12 100 25 >100 >100 
13 6.25 3.125 12.5 >100 
14 6.25 6.25 12.5 >100 
Ciprofloxacin 6.25 3.125 6.25 12.5 
a The value obtained in at least three separate assays done in triplicate. 
 




the cells with regular exposure for 48 h is displayed in 
Figure 2.Findings revealed that the toxic effect 
depends on concentration, such as at3.125 m the 
viability rages from 95-100% for all the active 
compounds including reference. As the concentration 
increases the viability decreases such as ≥90% (at 
25m) and ≥80% (at 50 & 100 µm) if the tested 
compounds did not exhibit remarkable toxic effects 
up to 100 µm as all exhibiting the viability of ≥80% at 
this concentration. 
 
Molecular docking Studies 
For the Molecular docking studies, the chemical 
structure of substituted 1,3,4-oxadiazoline derivatives 
drawn by using Chem3D Pro 14.0 (K. R Cousins; 
2011) which is shown in Figure 3. 3D structure of 
1,3,4-oxadiazoline derivatives docking outcome 
demonstrates that the synthesized 1,3,4-oxadiazole 
derivatives (Table I and Figure 4, Figure 5, Figure 6, 
Figure 7 and Figure 8) with E. coli protein peptide 
deformylase (S. Bala et al; 2014) shows the hydrogen 
bond interactions of amino acid residues and Chain 
ID. Docking studies (G. M Morris et al; 2009) shows 
the binding affinity of compound 3 is (-8.8) and 
interacting residues are His7(A), Ile44(A), Gly89(A), 
Leu91(A) and Glu95(A) in Figure 4, the binding 
affinity of compound 5 is -8.6 and interacting residues 
are Ile44(B), Gly45(B), His132(B) and Asp135(B) in 
Figure 5, the binding affinity of compound 11 is -8.6 
and the interacting residues are Gly89(B), Arg97(B), 
Cys90(B) and Glu95(B) in Figure 6, the binding 
affinity of compound 13 is -9.3 and the interacting 
residues Ile44(B), Gly45(B) and Arg97(B) in 
Figure 7, the binding affinity of compound 14 is -9.1 
and the  interacting  with B  chain  and  residues  are  
Table IV — Effect of compounds 1-14 on growth of microorganism by halo zone test. Ciprofloxacin used as standard drug and DMSO 
as negative control 
Compd Inhibitory effects of compounds on microorganisms 
 Gram positive (Gram+ve) Gram negative (Gram-ve) 
 S. aureus S. epidermidis P. mirabilis E. coli 
1 8.81±0.06 9.97±0.12 11.54±0.17 12.60±0.10 
2 8.24±0.18 8.59±0.28 9.68±0.51 7.59±0.40 
3 20.86±0.64 22.27±0.31 22.06±0.17 23.05±0.15 
4 11.85±1.44 14.19±0.92 12.71±0.14 9.56±0.21 
5 14.94±0.34 10.93±0.18 10.39±0.16 10.97±0.2 
6 8.61±0.18 15.61±0.40 9.09±0.21 8.79±0.74 
7 19.43±0.21 20.63±0.08 18.79±0.71 19.39±0.19 
8 18.24±0.18 21.40±0.30 19.50±0.14 18.52±0.24 
9 21.88±0.50 19.44±0.59 20.59±2.05 20.38±0.28 
10 12.39±0.15 8.94±0.94 8.07±0.14 12.54±0.18 
11 8.81±0.22 8.84±0.08 11.56±0.16 8.94±0.44 
12 10.24±0.18 16.43±0.45 12.61±0.08 9.43±0.21 
13 21.14±0.23 20.68±0.51 18.51±0.16 21.56±1.06 
14 19.46±0.28 18.41±0.25 19.58±0.34 21.45±0.23 
Ciprofloxacin 21.46±0.31 22.64±0.54 22.24±0.30 23.82±0.47 




Figure 1 — The graph showing comparative percent area
inhibition per µg of the compounds 1-14 and the Ciprofloxacin in
case of gram-positive bacteria (S. aureus and S. epidermidis)and




Figure 2 — Percent viability of cells after 48 h pre-treatment of
HepG2 cell line with active compounds and Ciprofloxacin by MTT
assay 
 





Ile44(B), Gly45(B), Arg97(B), His132(B), Asp135(B), 
and Asp162(A) in Figure 8 and the binding affinity of 
standard drug Ciprofloxacin is (-8.0) and the 
interacting residues Gln50(C), Leu91(C) and 
Glu133(C). Receptor-ligand binding interaction studies 
done by LigPlot (R.A Laskowski,M.B. Swindells; 
2011 and I.I. Hejaziet al; 2021) with peptide 
deformylase protein as mentioned Table V. The 
receptor protein has 3 chains so, the compound 3 
interacting with chain A, compound 5, 11, 13 and 14  
 
 
Figure 3 — Chemical structure of substituted oxadiazoline derivatives which shows in different colours green (R1), red (R2) and yellow 
(R3): (a) 1,3,4-oxadizoline analogue 3 (b) 1,3,4-oxadizoline analogue 5 (c) 1,3,4-oxadizoline analogue 11 (d) 1,3,4-oxadizoline analogue 




Figure 4 — Surface model of peptide deformylase in cavity compound 3 showing the protein compound interaction, where the interacting 
residues are His7, Ile44, Gly89, Leu91, Glu95 and Asp162. 
 





interacts with chain B and the interaction of standard 
drug with chain C. The docking score of synthesis 
derivatives (Compounds 3, 5, 11,13 and 14) was 
found higher in comparison to standard drug 
ciprofloxacin. These results could be used for the 
development of effective antimicrobial agents. In 
between ligand and receptor more than 3.2˚A distance 
indicates frail hydrogen bonding, in between 2.6˚A–
3.2˚A distance shows the virtuous hydrogen bonding, 
and  less  than  2.5˚  A   indicates  vigorous   bonding.  
 
 
Figure 5 — Surface model of peptide deformylase in cavity compound 5 showing the protein compound interaction, where the interacting 




Figure 6 — Surface model of peptide deformylase in cavity compound 11 showing the protein compound interaction, where the 
interacting residues are Gly89, Arg97, Cys90 and Glu95. 
 







Figure 7 — Surface model of peptide deformylase in cavity compound 13 showing the protein compound interaction, where the 




Figure 8 — Surface model of peptide deformylase in cavity compound 14 showing the protein compound interaction, where the 
interacting residues are Ile44, Gly45, Arg97, His132 and Asp135. 
 




Almost all the active derivatives showed good 
hydrogen bonding with protein. 
 
Conclusions 
Novel library of 1,3,4-oxadiazoline analogues with 
low molecular weight was synthesized by the following 
few step reactions to make cost effectual chemical that 
can be used as an antibacterial agent and targeted the  
S. aureus and S. epidermidis (Gram+ve) and P. mirabilis 
and E. coli (Gram-ve) bacteria. Accounting for the 
pharmacological potential of both nucleus oxadiazoline 
and nitro-imidazole the scheme was planned in such a 
manner for the targeted compounds will be having both 
significant functional moieties. All the substituted 
analogues of 1,3,4-oxadizoline (1-14) were screened for 
their antibacterial activity against Gram+ve and Gram-
ve bacteria discussed above. Several compounds showed 
outstanding activity evaluated with the standard drug 
Ciprofloxacin results are calculated in terms of zone of 
inhibition and MIC. Among them, some of the 
compounds performed good activity while some were 
found to have similar activity in a contrast to standard. 
Among all the synthesized compounds 3, 5, 11, 13 and 
14were found to be the most potent peptide-deformylase 
inhibitor with the highest dock score for compound 13 is 
-9.3 than that of standard drug Ciprofloxacin is -8.0. 
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